Join Foundation Medicine at the European Society for Medical Oncology (ESMO) Congress

Shaping the forefront of cancer care together.

Foundation Medicine is Your Essential Partner Across the Global Therapy Development Lifecycle.

Traditional therapy discovery and development is long, slow, and costly—but studies have shown that biomarkers can significantly reduce costs and accelerate the approval process. Our comprehensive portfolio of tests and data solutions can help your global therapy development programs reach patients faster with fewer costs. Learn more about our Biopharma Partnership Solutions here.

Visit Foundation Medicine at the Roche booth #501, 502

Join Foundation Medicine at this year’s ESMO as we present groundbreaking research, including new data from the phase II CUPISCO study and insights on our innovative HRD signature as a predictive biomarker in endometrial cancer. Explore the full list of abstracts below to learn more. Our HRDsig can identify more patients, including those with or without relevant HRR gene mutations, that may respond to PARP inhibitors. Learn more here 

Meet with Our Team

Posters and Presentations

Foundation Medicine will be presenting new research at this year's ESMO Congress featuring the following abstracts: 

Clinically Advanced Prostate Cancer (CAPC) Featuring BRACA2 Loss: A Comprehensive Genomic Profiling (CGP) Study

Authors:

Chiara Mercinelli, Neeraj Agarwal, Shilpa Gupta, Petros Grivas, Phillippe Spiess, Roger Li, Gennady Bratslavsky, Joseph Jacob, Alina Basnet, Dean Pavlick, Ryon Graf, Jeffrey Ross, Andrea Necchi

Collaborating Institutions:

HSR Milan

Outcomes for patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) and disease progression (PD) after induction chemotherapy (CTX) in the global, open-label, Phase II CUPISCO study

Authors:

Tilmann Bochtler, Alwin Krämer, Chantal Pauli, Gonzalo Durán-Pacheco, Cagatay Arslan, Frédéric Bigot, Nasséra Chalabi, Natalie Cook, Antoine Italiano, Ferran Losa, Juliana Janoski de Menezes, Ning Ma, Mustafa Özgüroğlu, Roberto A. Pazo-Cid, Jeffrey S. Ross, Kai-Keen Shiu; Panoraia Arni, Holger Moch, Linda Mileshkin

Collaborating Institutions:

German Cancer Research Center (DKFZ), University of Heidelberg and National Center for Tumor Diseases, Heidelberg University Hospital ; German Cancer Research Center (DKFZ) and University of Heidelberg; University Hospital Zürich and University of Zürich; F. Hoffmann-La Roche Ltd; Izmir University of Economics Medical Point Hospital; Institut de Cancérologie de l'Ouest; University of Manchester; Institut Bergonié; Hospital de Sant Joan Despí Moisès Broggi, ICO Hospitalet; Centro Pesquisa Integrado em Oncologia; İstanbul Üniversitesi-Cerrahpaşa; Miguel Servet University Hospital; Foundation Medicine; UCL Cancer Institute; Evang. Kliniken Essen-Mitte; Peter MacCallum Cancer Centre

Squamous Cell Carcinoma of Unknown Primary (SCCUP): A Genomic Landscape Study

Authors:

HR Robinson, S Lakritz, DC Pavlick, SL Davis, CH Lieu, CJ Eule, LR Graham, PE Spiess, R Li, AM Kamat, P Grivas, JM Jacob, G Bratslavsky, A Basnet, KA Wong, K Murugesan, DI Lin, A Necchi, JS Ross, ET Lam

Collaborating Institutions:

UC Denver

5-Methylthioadenosine phosphorylase (MTAP) Loss in Clinically Advanced Uveal Melanoma (CAUM): A Comprehensive Genomic Profiling (CGP) Study

Authors:

Nimisha Srivastava, Dean Pavlick, Sanchit Panda, Jeffrey Ross, Alina Basnet

Collaborating Institutions:

Upstate Medical University

D6 IMPACT 2: Final Results of a Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer at MD Anderson Cancer Center

Authors:

Apostolia Maria Tsimberidou, Siqing Fu, David S. Hong, Sarina A. Piha-Paul, Aung Naing, Jordi Rodon Ahnert, Timothy A. Yap, Daniel D. Karp, Ecaterina Elena Dumbrava, John Heymach, Jaffer A. Ajani, Carrie Cartwright, Jennifer Beck, Clark R. Andersen, Michael Kahle, David J. Vining, Jeffrey S. Ross, Calvin Y. Chao, Donald A. Berry, Funda Meric-Bernstam

Collaborating Institutions:

MDACC

A Genomic Scar Based Signature (HRDsig) and Biallelic BRCA Alterations Identify a Homologous Recombination Deficiency (HRD) Phenotype of Non-Small Cell Lung Cancer (NSCLC) that is Potentially Responsive to the PARP inhibitor Rucaparib: Post-Hoc Analysis

Authors:

Jonathan W. Riess, Jieling Miao, Paul Wheatley-Price, Karen L. Reckamp, David E. Kozono, Mary W. Redman, (1 TBA pending for NRG,);  Bryan Faller, Liza Villaruz,  Larry R. Corum, Aruna Gowda, Gordan Srkalovic, Raymond Osarogiagbon, Megan Baumgart,  David R. Gandara, Ethan Sokol, Hossein Borghaei, Jhanelle E. Gray, Roy S. Herbst, Karen Kelly

Collaborating Institutions:

1UC Davis Comprehensive Cancer Center, Sacramento, CA; 2SWOG Statistics and Data Management Center, Seattle, WA; 3University of Ottawa, Ottawa Hospital Cancer Centre, Ottawa, Ontario, CAN/CCTG; 4Cedars-Sinai Medical Center. Los Angeles, CA; 5Dana Farber Cancer Institute, Boston, MA 6Illinois CancerCare, Peoria, IL/Heartland NCORP;  7University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, PA/Alliance for Clinical Trials in Oncology; 8Olathe Cancer Care, Olathe KS/Kansas MU-NCORP; 9Licking Memorial Hospital, Newark, OH/Columbus NCORP); 10Sparrow Regional Cancer Center, Lansing, MI/Michigan Cancer Research Consortium NCORP; 11Baptist Memorial Hospital and Cancer Center-Memphis/Baptist MU-NCORP; 12University of Rochester, Rochester, NY; 13Foundation of Medicine, CambridgeBoston, MA; 14Fox Chase Cancer Center, Philadelphia, PA; 15Moffitt Cancer, Tampa, FL;  16 Yale University, New Haven, CT; 17 IASLC, Denver, CO

HRD Signature (HRDsig) in endometrial cancer (EC)

Authors:

Bhavana Pothuri, Brennan Decker, Ethan S. Sokol, Douglas I. Lin, Natalie Danziger, Shuoguo Wang, Alexa B. Schrock, Julia A. Elvin, Mia A. Levy, Hanna Tukachinsky

Collaborating Institutions:

Obstetrics and Gynecology Dept, Oncology Division, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, United States of America; Foundation Medicine

Clinical impact and landscape of heterogeneous ALK resistance mutations on comprehensive genomic profiling (CGP)

Authors:

Paul Hofman, Candice Francheska Tambaoan, Alexa B. Schrock, Gilles Erb, Russell Madison, Jessica K. Lee, Richard S. P. Huang

Collaborating Institutions:

IHU RespirERA, Laboratory of Clinical and Experimental Pathology; Foundation Medicine; F. Hoffmann-La Roche Ltd

Clinical validity of FoundationOne® Liquid CDx assay to identify BRCA+ patients in MAGNITUDE study

Authors:

Usha Singh, Yaji Xu, Lesley Farrington, Katherine Bell, Karen Urtishak, Won Kim, Jenny Zhang, Sarah Parsons, Flora Berisha, Kate Li, Melissa Schwenk, Wei Li, Songbai Wang

Collaborating Institutions:

Janssen Research & Development, LLC, Raritan, NJ, USA; Janssen Research & Development, LLC, Spring House, PA, USA; Janssen Research & Development, LLC, Los Angeles, CA, USA; Foundation Medicine, Inc., Cambridge, MA, USA